Edgewise Therapeutics, Inc.
EWTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001710072
In the last 90 days, Edgewise Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 226 institutions reported holding it in 13F filings for Q2 2026, worth $4.82B in total; no superinvestor holds it.
Holders of 5% or more of EWTX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Edgewise Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 13D/A | 14.50%15.3M shares | – | May 12, 20251 filing | May 12, 2025 | SEC |
| Ra Capital Management, L.P. | 13G/A | 9.90%10.4M shares | – | Nov 14, 20251 filing | Nov 14, 2025 | SEC |
| Baker Bros. Advisors LP | 13G/A | 6.90%7.31M shares | – | Aug 14, 20251 filing | Aug 14, 2025 | SEC |
| Paradigm Biocapital Advisors LP | 13G/A | 6.20%6.54M shares | +1.20 ppfrom 5.00% | Feb 3, 20252 filings | Feb 17, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 5.50%5.82M shares | – | Jul 17, 20251 filing | Jul 17, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
13 Schedule 13D and 13G filings on Edgewise Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 20264:02 PM ET | Paradigm Biocapital Advisors LPand 3 others | 13G/A | 6.20%6.54M shares | +1.20 ppfrom 5.00% | Dec 31, 2025 | SEC |
| Nov 14, 20254:15 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 9.90%10.4M shares | – | Sep 30, 2025 | SEC |
| Nov 14, 202510:24 AM ET | Janus Henderson Group PLC | 13G/A | 4.70%4.98M shares | −0.50 ppfrom 5.20%Below 5% | Sep 30, 2025 | SEC |
| Aug 14, 20254:28 PM ET | Baker Bros. Advisors LPand 3 others | 13G/A | 6.90%7.31M shares | – | Jun 30, 2025 | SEC |
| Aug 14, 20254:25 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 4.40%4.64M shares | −1.70 ppfrom 6.10%Below 5% | Jun 30, 2025 | SEC |
| Aug 14, 202511:44 AM ET | Janus Henderson Group PLC | 13G/A | 5.20%5.50M shares | −0.40 ppfrom 5.60% | Jun 30, 2025 | SEC |
| Jul 17, 20257:54 PM ET | BlackRock, Inc. | 13G/A | 5.50%5.82M shares | – | Jun 30, 2025 | SEC |
| May 15, 20254:30 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 6.10%6.40M shares | +0.60 ppfrom 5.50% | Mar 31, 2025 | SEC |
| May 14, 202512:29 PM ET | Janus Henderson Group PLC | 13G/A | 5.60%5.28M shares | +0.30 ppfrom 5.30% | Mar 31, 2025 | SEC |
| May 12, 20257:13 PM ET | OrbiMed Advisors LLCand 3 others | 13D/A | 14.50%15.3M shares | – | May 9, 2025 | SEC |
| Feb 21, 20255:57 PM ET | Perceptive Advisors LLCand 2 others | 13G | 5.50%5.16M shares | New | Feb 13, 2025 | SEC |
| Feb 14, 202511:24 AM ET | Janus Henderson Group PLC | 13G | 5.30%4.98M shares | New | Dec 31, 2024 | SEC |
| Feb 3, 20254:36 PM ET | Paradigm Biocapital Advisors LPand 3 others | 13G | 5.00%4.74M shares | New | Jan 27, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Edgewise Therapeutics, Inc. shares.
No Form 144 notices for Edgewise Therapeutics, Inc. are on file.